Promising cancer combo study halted early – only 4 black women enrolled
NCT ID NCT05263492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women with a certain type of recurrent endometrial cancer. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many patients responded to treatment after 24 weeks, but the small number of participants limits what can be learned.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?